A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
Key facts
- Who runs it
- The George Institute
- Where
- Australia8 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT07898462
- ACTRN12626000627358
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,200 people, planned
- Started
- 16 Oct 2026
- Expected to end
- 1 Mar 2031
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fludrocortisone 50 mcg daily
- Fludrocortisone 100 mcg daily
- Placebo
- Record updated
- 30 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Shock presumed due to infection
- Treatment with vasopressors to maintain a Systolic Blood Pressure (SBP) >90mmHg or Mean Arterial Pressure (MAP) > 65mmHg, after having received adequate fluid resuscitation (in the opinion of the treating clinician)
- Plasma lactate concentration >2mmol/L
- Being treated with hydrocortisone 200mg/day as adjunctive treatment for septic shock
- Being treated with one of the following:; Invasive Mechanical Ventilation OR; Non-invasive ventilation (CPAP or BiPAP) OR; Oxygen supplementation with an oxygen flow of >10L/min independent of delivery system and an FiO2 of 0.5 or above., OR; Use of Veno-venous ECMO
Who cannot take part
- Patients unable to receive enteral medications
- Receiving hydrocortisone (HC) or fludrocortisone (FC) for conditions other than septic shock
- Prior enrolment in this trial
- Patients with documented systemic fungal infection at the time of randomisation
- Patients with documented allergy to fludrocortisone
- An underlying disease process with a life expectancy of less than 28 days
- Met all inclusion criteria for more than 12 hours
- Death is deemed imminent or inevitable by treating ICU specialist
- Pregnancy (confirmed or suspected)
- Known or documented objections to research participation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The FLUDRO-SHOCK trial is a large international randomised controlled double-blinded study aiming to improve treatment for people with septic shock, a life-threatening condition caused by severe infection. Patients with septic shock receive a steroid called hydrocortisone, but it is unclear whether adding another steroid, fludrocortisone, improves their chances of recovery and survival. This study will test two doses of fludrocortisone (50 mcg and 100 mcg) against a placebo to see which works best. It will also explore whether a person's unique immune response, based on their genes, affects how well the treatment works. The trial will involve up to 2,200 critically ill adults in intensive care units across Australia and other countries. Researchers will track survival, organ recovery, and quality of life for up to a year. The goal is to find the most effective and personalised way to use steroids in septic shock, potentially saving lives and improving long-term outcomes.
The 3 groups in the trial
- Fludrocortisone 50 mcg dailyExisting treatment, for comparison
The intervention will be fludrocortisone acetate 50 mcg daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.
- Fludrocortisone 100 mcg dailyExisting treatment, for comparison
The intervention will be fludrocortisone acetate 100 mcg daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.
- PlaceboPlacebo, for comparison
Matching placebo tablet dosed daily, administered orally or via an in situ gastric tube for 7 days or until discharge from ICU, whichever is sooner.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunctive FLUDrocortisone With tRanscriptOme Evaluation in Septic SHOCK (FLUDRO-SHOCK)
- Record updated
- 30 October 2026